$OVID
Ovid Therapeutics Inc. Stock $ovid

$ovid Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024023067 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$169.0K	$148.0K
YoY Change	125.33%	123.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.104M	$7.168M
YoY Change	-1.75%	-14.09%
% of Gross Profit
Research & Development	$12.58M	$10.40M
YoY Change	109.74%	57.18%
% of Gross Profit
Depreciation & Amortization	$103.0K	$136.0K
YoY Change	-2.18%	-5.98%
% of Gross Profit
Operating Expenses	$20.69M	$17.57M
YoY Change	45.2%	17.43%
Operating Profit	-$20.52M	-$17.42M
YoY Change	44.77%	16.95%
Interest Expense	$38.00K	$5.723M
YoY Change	-97.21%	403.74%
% of Operating Profit
Other Income/Expense, Net	$29.04M	$5.723M
YoY Change	1546.47%	272.57%
Pretax Income	$8.521M	-$11.69M
YoY Change	-168.67%	-12.45%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$8.521M	-$11.69M
YoY Change	-168.67%	-12.45%
Net Earnings / Revenue	5042.01%	-7901.35%
Basic Earnings Per Share	$0.12	-$0.17
Diluted Earnings Per Share	$0.12	-$0.17
COMMON SHARES
Basic Shares Outstanding	70.94M shares	70.71M shares
Diluted Shares Outstanding	71.20M shares	70.72M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.97M	$90.26M
YoY Change	-20.25%	-23.33%
Cash & Equivalents	$29.69M	$30.77M
Short-Term Investments	$47.28M	$59.49M
Other Short-Term Assets	$3.915M	$2.911M
YoY Change	-30.75%	61.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$80.89M	$93.17M
YoY Change	-20.83%	-22.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$618.0K	$686.0K
YoY Change	-35.33%	-34.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$21.05M	$22.02M
YoY Change	27.82%	268.11%
Other Assets	$246.0K	$174.0K
YoY Change	-15.16%	-18.12%
Total Long-Term Assets	$37.20M	$38.44M
YoY Change	9.23%	61.2%
TOTAL ASSETS
Total Short-Term Assets	$80.89M	$93.17M
Total Long-Term Assets	$37.20M	$38.44M
Total Assets	$118.1M	$131.6M
YoY Change	-13.31%	-8.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.720M	$3.596M
YoY Change	25.42%	96.34%
Accrued Expenses	$8.108M	$4.039M
YoY Change	49.23%	-1.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.12M	$8.903M
YoY Change	39.22%	32.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$15.07M	$44.43M
YoY Change	-2.07%	183.03%
Total Long-Term Liabilities	$15.07M	$44.43M
YoY Change	-2.07%	183.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.12M	$8.903M
Total Long-Term Liabilities	$15.07M	$44.43M
Total Liabilities	$29.19M	$53.33M
YoY Change	14.33%	137.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$281.0M	-$289.6M
YoY Change	11.82%	21.22%
Common Stock	$71.00K	$71.00K
YoY Change	0.56%	0.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$88.90M	$78.28M
YoY Change
Total Liabilities & Shareholders Equity	$118.1M	$131.6M
YoY Change	-13.31%	-8.2%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$8.521M	-$11.69M
YoY Change	-168.67%	-12.45%
Depreciation, Depletion And Amortization	$103.0K	$136.0K
YoY Change	-2.18%	-5.98%
Cash From Operating Activities	-$14.26M	-$16.70M
YoY Change	21.79%	38.02%
INVESTING ACTIVITIES
Capital Expenditures	$150.0K	$19.00K
YoY Change	27.74%	40.12%
Acquisitions
YoY Change
Other Investing Activities	$12.97M	$20.21M
YoY Change	-35.73%	-33.18%
Cash From Investing Activities	$12.82M	$20.19M
YoY Change	-36.1%	-33.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	356.0K	$228.0K
YoY Change	68.64%	240.33%
NET CHANGE
Cash From Operating Activities	-14.26M	-$16.70M
Cash From Investing Activities	12.82M	$20.19M
Cash From Financing Activities	356.0K	$228.0K
Net Change In Cash	-1.078M	$3.716M
YoY Change	-112.58%	-79.58%
FREE CASH FLOW
Cash From Operating Activities	-$14.26M	-$16.70M
Capital Expenditures	$150.0K	$19.00K
Free Cash Flow	-$14.41M	-$16.72M
YoY Change	21.85%	38.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70691992	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70691992	shares
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10397000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6615000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7168000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8344000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	17565000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14958000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17417000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14892000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5723000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1536000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11694000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13356000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11694000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13356000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70716929	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70490704	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70716929	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70490704	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11694000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13356000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-20000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	48000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11714000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13308000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87797000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	228000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1968000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-20000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11694000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78279000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	132273000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	67000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1917000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	48000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13356000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	120948000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13356000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	4397000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	360000	usd
CY2024Q1	ovid	Change In Accrued Interest And Accretion Of Discounts Short Term Investments ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments	-921000	usd
CY2023Q1	ovid	Change In Accrued Interest And Accretion Of Discounts Short Term Investments ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments	-729000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1968000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1917000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	136000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	145000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	266000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	253000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-303000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	289000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-853000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-258000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-12000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-107000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-121000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2486000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-419000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16686000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12112000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9793000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9758000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	30000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	40000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20188000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30229000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	228000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	67000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	228000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3731000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	18184000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28972000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46799000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32703000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64982000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	90300000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	223000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289600000	usd
CY2024Q1	ovid	Working Capital WorkingCapital	84300000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16700000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	78792000	usd
CY2023Q4	ovid	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	105833000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2024Q1	us-gaap	Cash Cash	1320000	usd
CY2024Q1	us-gaap	Cash Cash	1320000	usd
CY2024Q1	ovid	Cash Equivalents Amortized Cost CashEquivalentsAmortizedCost	29452000	usd
CY2024Q1	ovid	Cash Equivalents Unrealized Holding Gains CashEquivalentsUnrealizedHoldingGains	0	usd
CY2024Q1	ovid	Cash Equivalents Unrealized Holding Losses CashEquivalentsUnrealizedHoldingLosses	0	usd
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	29452000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	59506000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	59487000	usd
CY2024Q1	ovid	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	90278000	usd
CY2024Q1	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Gain DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain	0	usd
CY2024Q1	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Loss DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss	19000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	90259000	usd
CY2023Q4	us-gaap	Cash Cash	2701000	usd
CY2023Q4	us-gaap	Cash Cash	2701000	usd
CY2023Q4	ovid	Cash Equivalents Amortized Cost CashEquivalentsAmortizedCost	24340000	usd
CY2023Q4	ovid	Cash Equivalents Unrealized Holding Gains CashEquivalentsUnrealizedHoldingGains	0	usd
CY2023Q4	ovid	Cash Equivalents Unrealized Holding Losses CashEquivalentsUnrealizedHoldingLosses	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	24340000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	78791000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Gain DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain	1000	usd
CY2023Q4	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Loss DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	105833000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1102000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1001000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	686000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	769000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	101000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	108000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	35000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q1	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	19000	sqft
CY2024Q1	ovid	Lessee Operating Lease Base Rent LesseeOperatingLeaseBaseRent	2300000	usd
CY2022Q1	ovid	Lessee Operating Lease Rent Payments Commencement Following This Period LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod	P10M
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P9Y
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2024Q1	ovid	Lease Incremental Borrowing Rate LeaseIncrementalBorrowingRate	0.0702
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13628000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1268000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14430000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	542000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1737000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2316000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2316000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2316000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2469000	usd
CY2024Q1	ovid	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	9878000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21033000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1527000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4277000	usd
CY2024Q1	ovid	Accrued Research And Development AccruedResearchAndDevelopment	1741000	usd
CY2023Q4	ovid	Accrued Research And Development AccruedResearchAndDevelopment	1396000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	380000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	522000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	391000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	331000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4039000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6525000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	ovid	Common Stock Number Of Votes For Each Share CommonStockNumberOfVotesForEachShare	1	vote
CY2024Q1	us-gaap	Dividends Dividends	0	usd
CY2024Q1	us-gaap	Dividends Dividends	0	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1968000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1916000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1968000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1916000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15124546	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.87
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5212286	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2672150	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.68
CY2024Q1	ovid	Share Based Compensation By Share Based Payment Award Options Granted Contractual Life ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife	P9Y11M1D
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	76908	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.47
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	363211	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.55
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17356577	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.77
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3850510	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	10596135	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.15
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y9M25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2370416	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16400000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M17D
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	ovid	Collaboration And Option Agreement Research Plan And Budget Expected Costs CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts	3000000	usd
CY2023Q2	ovid	Collaboration And Option Agreement Research Plan And Budget Expected Costs CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts	3500000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11694000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13356000	usd
CY2024Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2023Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11694000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13356000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11694000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13356000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70716929	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70490704	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70716929	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70490704	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-023067-index-headers.html	Edgar Link	pending
0001628280-24-023067-index.html	Edgar Link	pending
0001628280-24-023067.txt	Edgar Link	pending
0001628280-24-023067-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ovid-20240331.htm	Edgar Link	pending
ovid-20240331.xsd	Edgar Link	pending
ovid-20240331_g1.gif	Edgar Link	pending
ovid2024q1exhibit311.htm	Edgar Link	pending
ovid2024q1exhibit312.htm	Edgar Link	pending
ovid2024q1exhibit321.htm	Edgar Link	pending
ovidformofrsugrantpackag.htm	Edgar Link	pending
ovidformofrsugrantpackag001.jpg	Edgar Link	pending
ovidformofrsugrantpackag002.jpg	Edgar Link	pending
ovidformofrsugrantpackag003.jpg	Edgar Link	pending
ovidformofrsugrantpackag004.jpg	Edgar Link	pending
ovidformofrsugrantpackag005.jpg	Edgar Link	pending
ovidformofrsugrantpackag006.jpg	Edgar Link	pending
ovidformofrsugrantpackag007.jpg	Edgar Link	pending
ovidformofrsugrantpackag008.jpg	Edgar Link	pending
ovidformofrsugrantpackag009.jpg	Edgar Link	pending
ovidformofrsugrantpackag010.jpg	Edgar Link	pending
ovidnorthwesternlicensea.htm	Edgar Link	pending
ovidnorthwesternlicensea001.jpg	Edgar Link	pending
ovidnorthwesternlicensea002.jpg	Edgar Link	pending
ovidnorthwesternlicensea003.jpg	Edgar Link	pending
ovidnorthwesternlicensea004.jpg	Edgar Link	pending
ovidnorthwesternlicensea005.jpg	Edgar Link	pending
ovidnorthwesternlicensea006.jpg	Edgar Link	pending
ovidnorthwesternlicensea007.jpg	Edgar Link	pending
ovidnorthwesternlicensea008.jpg	Edgar Link	pending
ovidnorthwesternlicensea009.jpg	Edgar Link	pending
ovidnorthwesternlicensea010.jpg	Edgar Link	pending
ovidnorthwesternlicensea011.jpg	Edgar Link	pending
ovidnorthwesternlicensea012.jpg	Edgar Link	pending
ovidnorthwesternlicensea013.jpg	Edgar Link	pending
ovidnorthwesternlicensea014.jpg	Edgar Link	pending
ovidnorthwesternlicensea015.jpg	Edgar Link	pending
ovidnorthwesternlicensea016.jpg	Edgar Link	pending
ovidnorthwesternlicensea017.jpg	Edgar Link	pending
ovidnorthwesternlicensea018.jpg	Edgar Link	pending
ovidnorthwesternlicensea019.jpg	Edgar Link	pending
ovid-20240331_cal.xml	Edgar Link	unprocessable
ovid-20240331_def.xml	Edgar Link	unprocessable
ovid-20240331_lab.xml	Edgar Link	unprocessable
ovid-20240331_pre.xml	Edgar Link	unprocessable
ovid-20240331_htm.xml	Edgar Link	completed
ovidnorthwesternlicensea020.jpg	Edgar Link	pending
ovidnorthwesternlicensea021.jpg	Edgar Link	pending
ovidnorthwesternlicensea022.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OVID
Ovid Therapeutics Inc. Stock $ovid

2024 Q2 Form 10-Q Financial Statement

#000162828024023067 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OVID Ovid Therapeutics Inc. Stock $ovid

2024 Q2 Form 10-Q Financial Statement

#000162828024023067 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OVID
Ovid Therapeutics Inc. Stock $ovid